{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T06:28:38Z","timestamp":1775197718966,"version":"3.50.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.vaccine.2023.02.007","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T09:49:07Z","timestamp":1677232147000},"page":"2155-2169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Factors associated with yellow fever vaccine failure: A systematic literature review"],"prefix":"10.1016","volume":"41","author":[{"given":"Francieli Fontana Sutile Tardetti","family":"Fantinato","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia Kagure","family":"Wachira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor Bertollo Gomes","family":"Porto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry Maia","family":"Peixoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth Carmen","family":"Duarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.02.007_b0005","doi-asserted-by":"crossref","unstructured":"Vasconcelos PFDC. Febre amarela: reflex\u00f5es sobre a doen\u00e7a, as perspectivas para o s\u00e9culo XXI e o risco da reurbaniza\u00e7\u00e3o. Rev Bras Epidemiol [Internet]. 2002;5(3):244\u201358. Available from: http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S1415- 790X2002000300004&lng=pt&nrm=iso&tlng=pt.","DOI":"10.1590\/S1415-790X2002000300004"},{"key":"10.1016\/j.vaccine.2023.02.007_b0015","unstructured":"World Health Organization (WHO). Division of Epidemiological Surveillance and Health Situation and Trend Assessment Global Health Situation and Projections: Estimates. Geneve: World Health Organization; 1992. 94 p."},{"key":"10.1016\/j.vaccine.2023.02.007_b0020","unstructured":"Pan American Health Organization. Epidemiological Update Yellow Fever \u2013 20 March. Paho. 2019. p. 1\u20137."},{"key":"10.1016\/j.vaccine.2023.02.007_b0025","unstructured":"World Health Organization. Yellow fever. 2019. p. https:\/\/www.who.int\/news- room\/fact-sheets\/detail\/y."},{"key":"10.1016\/j.vaccine.2023.02.007_b0030","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijid.2017.11.026","article-title":"Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus","volume":"67","author":"Leta","year":"2017","journal-title":"Int J Infect Dis"},{"issue":"9","key":"10.1016\/j.vaccine.2023.02.007_b0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0005897","article-title":"Geographic patterns and environmental factors associated with human yellow fever presence in the Americas","volume":"11","author":"Hamrick","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2023.02.007_b0040","doi-asserted-by":"crossref","unstructured":"Monath TP. Yellow fever vaccine. Meyler\u2019s Side Eff Drugs [Internet]. 2016;537\u201340. Available from: http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/B9780444537171016504.","DOI":"10.1016\/B978-0-444-53717-1.01650-4"},{"key":"10.1016\/j.vaccine.2023.02.007_b0045","unstructured":"States M, Strategic WHO, Group A, Grade T, Sage T. Weekly epidemiological record Relev\u00e9 \u00e9pid\u00e9miologique hebdomadaire. 2017;(34):477\u2013500."},{"key":"10.1016\/j.vaccine.2023.02.007_b0050","doi-asserted-by":"crossref","unstructured":"Monath TP, Vasconcelos PFC. Yellow fever. J Clin Virol [Internet]. 2015;64:160\u201373. Available from: http:\/\/dx.doi.org\/10.1016\/j.jcv.2014.08.030.","DOI":"10.1016\/j.jcv.2014.08.030"},{"key":"10.1016\/j.vaccine.2023.02.007_b0055","unstructured":"Minist\u00e9rio da Sa\u00fade Secretaria de Vigil\u00e2ncia em Sa\u00fade Departamento de Vigil\u00e2ncia das Doen\u00e7as Transmiss\u00edveis B. Biblioteca Virtual em Sa\u00fade do Minist\u00e9rio da Sa\u00fade www.saude.gov.br\/bvs [Internet]. 2014. 1\u2013254 p. Available from: http:\/\/editora.saude.gov.br."},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.007_b0060","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/21645515.2015.1093263","article-title":"Primary vaccine failure to routine vaccines: Why and what to do?","volume":"12","author":"Wiedermann","year":"2016","journal-title":"Hum Vaccines Immunother"},{"issue":"7","key":"10.1016\/j.vaccine.2023.02.007_b0065","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.vaccine.2023.02.007_b0070","unstructured":"Francieli Fontana Sutile Tardetti Fantinato, Elisabeth Carmen Duarte HMP. Factors associated with vaccine failure with the Yellow Fever Vaccine. A Systematic Review. National Institute for Health Research. 2020. p. International prospective register of systematic."},{"key":"10.1016\/j.vaccine.2023.02.007_b0075","unstructured":"Green JPH and S, editor. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Collaboration; 2011."},{"key":"10.1016\/j.vaccine.2023.02.007_b0080","doi-asserted-by":"crossref","unstructured":"Miyaji KT, Avelino-Silva VI, Sim\u00f5es M, Freire M da S, Medeiros CR de, Braga PE, et al. Prevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adults. Rev Inst Med Trop S\u00e4o Paulo [Internet]. 2017;59: e2\u2013e2. Available from: http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0036-46652017005000200.","DOI":"10.1590\/s1678-9946201759002"},{"issue":"4","key":"10.1016\/j.vaccine.2023.02.007_b0085","doi-asserted-by":"crossref","first-page":"e1993","DOI":"10.1371\/journal.pone.0001993","article-title":"Intradermally administered yellow fever vaccine at reduced dose induces a protective immune response: a randomized controlled non-inferiority trial","volume":"3","author":"Roukens","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.007_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2334-14-391","article-title":"Subdoses of 17DD yellow fever vaccine elicit equivalent virological\/immunological kinetics timeline","volume":"14","author":"Campi-Azevedo","year":"2014","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.007_b0095","doi-asserted-by":"crossref","unstructured":"Jia Q, Jia C, Liu Y, Yang Y, Qi J, Tong L, et al. Clinical evidence for the immunogenicity and immune persistence of vaccination with yellow fever virus strain 17D in Chinese peacekeepers deployed to Africa. Antiviral Res [Internet]. 2019 Feb;162(October 2018):1\u20134. Available from: https:\/\/doi.org\/10.1016\/j.antiviral.2018.12.001.","DOI":"10.1016\/j.antiviral.2018.12.001"},{"key":"10.1016\/j.vaccine.2023.02.007_b0100","doi-asserted-by":"crossref","unstructured":"Guerra HL, Sardinha TM, Rosa APAT, Costa MFL e. Efetividade da vacina antiamar\u00edlica 17D: uma avalia\u00e7\u00e3o epidemiol\u00f3gica em servi\u00e7os de sa\u00fade. Rev Panam Salud P\u00fablica. 1997;2(2):115\u201320.","DOI":"10.1590\/S1020-49891997000800004"},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.007_b0105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0027753","article-title":"Elderly subjects have a delayed antibody response and prolonged viraemia following yellow fever vaccination: A prospective controlled cohort study","volume":"6","author":"Roukens","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.vaccine.2023.02.007_b0110","unstructured":"Osei-Kwasi M, Dunyo SK, Koram KA, Afari EA, Odoom JK, Nkrumah FK, et al. Antibody response to 17D yellow fever vaccine in Ghanaian infants. Bull World Health Organ [Internet]. 2001;79(11):1056\u20139. Available from: http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id =L33078675."},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.007_b0115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0092-1157(89)90023-1","article-title":"Study of combined vaccination against yellow fever and measles in infants from six to nine months","volume":"17","author":"Lhuillier","year":"1989","journal-title":"J Biol Stand"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2023.02.007_b0120","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1093\/cid\/civ603","article-title":"Immunogenicity of yellow fever vaccine coadministered with MenAfriVac in healthy infants in Ghana and Mali","volume":"61","author":"Chowdhury","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2023.02.007_b0125","doi-asserted-by":"crossref","unstructured":"Ambrosch F, Fritzell B, Gregor J, Jonas S, Kollaritsch H, Teulieres L, et al. Combined vaccination against yellow fever and typhoid fever: A comparativetrial. Vaccine [Internet]. 1994 May;12(7):625\u20138. Available from: http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id =L24153529.","DOI":"10.1016\/0264-410X(94)90267-4"},{"issue":"10","key":"10.1016\/j.vaccine.2023.02.007_b0130","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/INF.0000000000001250","article-title":"Immunogenicity and Safety of Yellow Fever Vaccine (Stamaril) When Administered Concomitantly With a Tetravalent Dengue Vaccine Candidate in Healthy Toddlers at 12\u201313 Months of Age in Colombia and Peru: A Randomized Trial","volume":"35","author":"Lopez","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.02.007_b0135","doi-asserted-by":"crossref","unstructured":"Nascimento Silva JR, Camacho LAB, Siqueira MM, Freire M de S, Castro YP, Maia M de LS, et al. Mutual interference on the immune response to yellow fever vaccine and a combined vaccine against measles, mumps and rubella. Vaccine. 2011;29(37):6327\u201334.","DOI":"10.1016\/j.vaccine.2011.05.019"},{"key":"10.1016\/j.vaccine.2023.02.007_b0140","unstructured":"Adu FD, Omotade OO, Oyedele OI I, O, Odemuyiwa SO O AL. Field trial of combined yellow fever and measles vaccines among children in Nigeria. East Afr Med J [Internet]. 1996 Sep;73(9):579\u201382. Available from: http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id =L27191592."},{"key":"10.1016\/j.vaccine.2023.02.007_b0145","doi-asserted-by":"crossref","unstructured":"Clarke E, Saidu Y AJ et al. Safety and immunogenicity of inactivated poliovirus vaccine when given with measles\u2013rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia. Lancet Glob Heal [Internet]. 2016;4(8):e534\u201347. Available from: http:\/\/dx.doi.org\/10.1016\/S2214- 109X(16)30075-4.","DOI":"10.1016\/S2214-109X(16)30075-4"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.007_b0150","first-page":"175","article-title":"Simultaneous administration of smallpox, measles, yellow fever, and diphtheria-pertussis-tetanus antigens to Nigerian children","volume":"48","author":"Ruben","year":"1973","journal-title":"Bull World Health Organ"},{"issue":"4","key":"10.1016\/j.vaccine.2023.02.007_b0155","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1093\/infdis\/jiy215","article-title":"Evaluation of a booster dose of pentavalent rotavirus vaccine coadministered with measles, yellow fever, and meningitis a Vaccines in 9-Month-old Malian infants","volume":"218","author":"Haidara","year":"2018","journal-title":"J Infect Dis [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.007_b0160","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/jmv.1890170106","article-title":"Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine","volume":"17","author":"Kayser","year":"1985","journal-title":"J Med Virol [Internet]"},{"issue":"11","key":"10.1016\/j.vaccine.2023.02.007_b0165","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4161\/hv.6.11.12854","article-title":"Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity","volume":"6","author":"Nasveld","year":"2010","journal-title":"Hum Vaccin"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.007_b0170","doi-asserted-by":"crossref","first-page":"66","DOI":"10.2310\/7060.2002.21955","article-title":"An open randomized study of inactivated hepatitis A vaccine administered concomitantly with typhoid fever and yellow fever vaccines","volume":"9","author":"Jong","year":"2002","journal-title":"J Travel Med [Internet]"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.007_b0175","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/jtm.12164","article-title":"Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal acwy glycoconjugate vaccine in healthy adults","volume":"22","author":"Alberer","year":"2015","journal-title":"J Travel Med [Internet]"},{"key":"10.1016\/j.vaccine.2023.02.007_b0180","first-page":"205","article-title":"Simultaneous administration of hepatitis B and yellow fever vaccines","volume":"65","author":"Yvonnet","year":"1986","journal-title":"Dev Biol Stand"},{"issue":"20","key":"10.1016\/j.vaccine.2023.02.007_b0185","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1016\/j.vaccine.2015.03.069","article-title":"Observational study on immune response to yellow fever and measles vaccines in 9 to 15-month old children. Is it necessary to wait 4 weeks between two live attenuated vaccines?","volume":"33","author":"Michel","year":"2015","journal-title":"Vaccine [Internet]"},{"issue":"45","key":"10.1016\/j.vaccine.2023.02.007_b0190","doi-asserted-by":"crossref","first-page":"6166","DOI":"10.1016\/j.vaccine.2017.09.047","article-title":"CHRONOVAC VOYAGEUR: A study of the immune response to yellow fever vaccine among infants previously immunized against measles","volume":"35","author":"Goujon","year":"2017","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.007_b0195","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow Fever 17D Vaccine Safety and Immunogenicity in the Elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum Vaccin [Internet]"},{"key":"10.1016\/j.vaccine.2023.02.007_b0200","first-page":"1","volume":"2017","author":"Miyaji","year":"2016","journal-title":"Antibodies in Previously Vaccinated Adults"},{"issue":"4","key":"10.1016\/j.vaccine.2023.02.007_b0205","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/infdis\/154.4.726","article-title":"Chloroquine Does Not Adversely Affect the Antibody Response to Yellow Fever Vaccine","volume":"154","author":"Tsai","year":"1986","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.007_b0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4269\/ajtmh.1991.44.79","article-title":"The effect of chloroquine prophylaxis on yellow fever vaccine antibody response: comparison of plaque reduction neutralization test and enzyme-linked immunosorbent assay","volume":"44","author":"Barry","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.02.007_b0215","doi-asserted-by":"crossref","unstructured":"Crawley J, Sismanidis C, Goodman T, Milligan P. Effect of intermittent preventive treatment for malaria during infancy on serological responses to measles and other vaccines used in the Expanded Programme on Immunization: results from five randomised controlled trials. Lancet [Internet]. 2012 Sep;380(9846):1001\u201310. Available from: http:\/\/dx.doi.org\/10.1016\/S0140- 6736(12)60775-2.","DOI":"10.1016\/S0140-6736(12)60775-2"},{"key":"10.1016\/j.vaccine.2023.02.007_b0220","doi-asserted-by":"crossref","unstructured":"Martins RM, Maia M de LS, Farias RHG, Camacho LAB, Freire MS, Galler R, et al. 17DD yellow fever vaccine: A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study. Hum Vaccines Immunother [Internet]. 2013 Apr 27;9(4):879\u201388. Available from: http:\/\/www.tandfonline.com\/doi\/abs\/10.4161\/hv.22982.","DOI":"10.4161\/hv.22982"},{"key":"10.1016\/j.vaccine.2023.02.007_b0225","article-title":"Duration of humoral and cellular immunity 8 years after administration of reduced doses of the 17DD-yellow fever vaccine","author":"Da Costa-Rocha","year":"2019","journal-title":"Front Immunol [Internet]"},{"issue":"11","key":"10.1016\/j.vaccine.2023.02.007_b0230","doi-asserted-by":"crossref","first-page":"761","DOI":"10.7326\/M18-1529","article-title":"Long-Term ProtectionAfter Fractional-Dose Yellow Fever Vaccination: follow-up Study of a Randomized, Controlled, Noninferiority Trial","volume":"169","author":"Roukens","year":"2018","journal-title":"Ann Intern Med [Internet]"},{"key":"10.1016\/j.vaccine.2023.02.007_b0235","doi-asserted-by":"crossref","unstructured":"Lopes Ode S, Guimaraes SS, de Carvalho R. Studies on yellow fever vaccine. III- -Dose response in volunteers. J Biol Stand. 1988 Apr;16(2):77\u201382.","DOI":"10.1016\/0092-1157(88)90034-0"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.007_b0240","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.jaci.2013.10.037","article-title":"Transcutaneous yellow fever vaccination of subjects with or without atopic dermatitis","volume":"133","author":"Slifka","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.vaccine.2023.02.007_b0245","doi-asserted-by":"crossref","unstructured":"Belmusto-Worn VE, Sanchez JL, McCarthy K, Nichols R, Bautista CT, Magill AJ, et al. Randomized, double-blind, phase III. Pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D 615 vaccines (ARILVAXTM and YF-VAX\u00ae) in healthy infants and children in Peru. 616 Am J Trop Med Hyg [Internet]. 2005;72(2):189\u201397. Available from: http:\/\/www.embase.com\/search\/results?subaction=viewrecord&from=export&id =L41278904.","DOI":"10.4269\/ajtmh.2005.72.189"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.007_b0250","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1590\/S0034-89102004000500009","article-title":"Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines : a 621 randomized trial Imunogenicidade das vacinas contra febre amarela WHO-17D e 622 17DD : ensaio randomizado","volume":"38","author":"Antonio","year":"2004","journal-title":"Rev Saude Publica"},{"key":"10.1016\/j.vaccine.2023.02.007_b0255","doi-asserted-by":"crossref","unstructured":"A randomised double-blind clinical trial of two yellow fever vaccines prepared with substrains 17DD and 17D-213\/77 in children nine-23 months old. Mem Inst Oswaldo Cruz. 2015 Sep;110(6):771\u201380.","DOI":"10.1590\/0074-02760150176"},{"issue":"3","key":"10.1016\/j.vaccine.2023.02.007_b0260","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4269\/ajtmh.2005.72.339","article-title":"Immunogenicity and safety of BERNA-YF compared with two other 17D yellow 628 fever vaccines in a phase 3 clinical trial","volume":"72","author":"Pfister","year":"2005","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.007_b0265","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2023.02.007_b0270","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","article-title":"Comparison of the immunogenicity and safety of two 17D yellow fever vaccines","volume":"60","author":"Lang","year":"1999","journal-title":"Am J Trop Med Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2023.02.007_b0275","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.jinf.2016.02.017","article-title":"17D yellow fever vaccine elicits comparable long-term immune 639 responses in healthy individuals and immune-compromised patients","volume":"72","author":"Wieten","year":"2016","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2023.02.007_b0280","doi-asserted-by":"crossref","unstructured":"Lindsey NP, Horiuchi KA, Fulton C, Panella AJ, Kosoy OI, Velez JO, et al. Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers. J Travel Med. 2018 Jan;25(1).","DOI":"10.1093\/jtm\/tay108"},{"key":"10.1016\/j.vaccine.2023.02.007_b0285","unstructured":"Noronha TG, de Lourdes de Sousa Maia M, Geraldo Leite Ribeiro J, Campos Lemos JA, Maria Barbosa de Lima S, Martins-Filho OA, et al. Duration of post-vaccination humoral immunity against yellow fever in children. Vaccine. 2019 Oct;"},{"issue":"2","key":"10.1016\/j.vaccine.2023.02.007_b0290","first-page":"125","article-title":"Failure of antibody production to yellow fever vaccine in children with kwashiorkor","volume":"18","author":"Brown","year":"1966","journal-title":"Trop Geogr Med"},{"issue":"1","key":"10.1016\/j.vaccine.2023.02.007_b0295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/hiv.09.52","article-title":"Yellow fever vaccination in HIV-infected patients","volume":"4","author":"Veit","year":"2010","journal-title":"HIV Ther [Internet]"},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.007_b0300","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1097\/00006454-199712000-00015","article-title":"Poor antibody response to yellow fever vaccination in children infected with human immunodeficiency virus type 1","volume":"16","author":"Sibailly","year":"1997","journal-title":"Pediatr Infect Dis J [Internet]"},{"issue":"12","key":"10.1016\/j.vaccine.2023.02.007_b0305","doi-asserted-by":"crossref","first-page":"e0005219","DOI":"10.1371\/journal.pntd.0005219","article-title":"CD4\/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients","volume":"10","author":"Avelino-Silva","year":"2016","journal-title":"PLoS Negl Trop Dis"},{"issue":"3","key":"10.1016\/j.vaccine.2023.02.007_b0310","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0035-9203(93)90156-K","article-title":"Yellow fever vaccination and pregnancy: A four-year prospective study","volume":"87","author":"Nasidi","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2023.02.007_b0315","doi-asserted-by":"crossref","unstructured":"Camacho LAB, Freire M da S, Leal M da LF, Aguiar SG de, Nascimento JP do, Iguchi T, et al. Immunogenicity of WHO-17D and Brazilian 17DD yellow fever vaccines: a randomized trial. Rev Saude Publica. 2004 Oct;38(5):671\u20138.","DOI":"10.1590\/S0034-89102004000500009"},{"key":"10.1016\/j.vaccine.2023.02.007_b0320","doi-asserted-by":"crossref","unstructured":"de Menezes Martins R, Maia M de LS, de Lima SMB, de Noronha TG, Xavier JR, Camacho LAB, et al. Duration of post-vaccination immunity to yellow fever in volunteers eight years after a dose-response study. Vaccine [Internet]. 2018;36(28):4112\u20137. Available from: https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.041.","DOI":"10.1016\/j.vaccine.2018.05.041"},{"key":"10.1016\/j.vaccine.2023.02.007_b0325","article-title":"Produ\u00e7\u00e3o de vacina contra Febre Amarela por laborat\u00f3rio oficial durante epidemia: situa\u00e7\u00e3o cr\u00edtica do estoque e estrat\u00e9gia para cumprimento da demanda","author":"Costa","year":"2019","journal-title":"Funda\u00e7\u00e3o Oswaldo Cruz"},{"issue":"5","key":"10.1016\/j.vaccine.2023.02.007_b0330","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ogrm.2013.03.005","article-title":"Clinicians in leadership and management in the National Health Service","volume":"23","author":"Lim","year":"2013","journal-title":"Obstet Gynaecol Reprod Med"},{"key":"10.1016\/j.vaccine.2023.02.007_b0335","unstructured":"MINIST\u00c9RIO DA SA\u00daDE Secretaria de Vigil\u00e2ncia em Sa\u00fade Departamento de Imuniza\u00e7\u00e3o e Doen\u00e7as, Transmiss\u00edveis. Guia de tratamento da mal\u00e1ria no Brasil [Internet]. 1a edi\u00e7\u00e3o. Coordena\u00e7\u00e3o-Geral de Documenta\u00e7\u00e3o e Informa\u00e7\u00e3o \u2013 Editora MS, editor. Vol. 67, Minist\u00e9rio da Sa\u00fade. Bras\u00edlia; 2020. 1\u201378 p. Available from: https:\/\/bvsms.saude.gov.br\/bvs\/publicacoes\/guia_tratamento_malaria_brasil.pdf."},{"key":"10.1016\/j.vaccine.2023.02.007_b0340","unstructured":"Brasil, Minist\u00e9rio da Sa\u00fade, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Departamento deImuniza\u00e7\u00e3o e Doen\u00e7as Transmiss\u00edveis. Manual dos Centros de Refer\u00eancia para Imunobiol\u00f3gicos Especiais. 5. ed. Editora MS, editor. Brasilia; 2019."},{"issue":"6","key":"10.1016\/j.vaccine.2023.02.007_b0345","first-page":"1055","article-title":"Field evaluation of vaccine efficacy","volume":"63","author":"Orenstein","year":"1985","journal-title":"Bull World Health Organ"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001330?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23001330?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:25:52Z","timestamp":1759404352000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23001330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":68,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S0264410X23001330"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.007","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Factors associated with yellow fever vaccine failure: A systematic literature review","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}